Immunohistochemical localization of metallothionein in endometrial lesions

被引:3
作者
Ioachim, EE [1 ]
Kitsiou, E [1 ]
Carassavoglou, C [1 ]
Stefanaki, S [1 ]
Agnantis, NJ [1 ]
机构
[1] Univ Ioannina, Sch Med, Dept Pathol, Ioannina 45110, Greece
关键词
metallothionein; ER; PgR; p53; bcl-2; PCNA; MIB1; endometrial lesions;
D O I
10.1002/1096-9896(2000)9999:9999<::AID-PATH616>3.0.CO;2-Q
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Metallothioneins (MTs) are a group of ubiquitous low-molecular-weight proteins essential for the protection of cells against heavy metal ion toxicity. The immunohistochemical expression of MT was studied by immunohistochemistry using a monoclonal antibody (E9) against a conserved epitope of I and II isoforms in a series of 89 endometrial carcinomas, 34 cases of hyperplasia, and 32 samples of normal endometrium, In secretory phase endometrium, extensive MT expression was detected in most cases (92.4%), In contrast, MT immunoreactivity was confined to small foci in 22.2% of proliferative phase cases. The MT values in normal endometrium were inversely correlated with oestrogen receptor (ER) content (p<0.0001), progesterone receptor (PgR) content and with PCNA (p<0.0001) and MIB1 (p=0.001) scores. In hyperplastic lesions, MT expression was detected only in 3.3% of cases, while in the group of carcinomas it was observed in 23.1%, A statistically significant difference of MT expression was observed between carcinomas and simple hyperplasias (p=0.03). In carcinomas, MT expression was positively correlated with grade (p=0.0065), MIB1 (p=0.022), and p53 (p=0.006) expression, and inversely with PgR (p=0.03). A trend of inverse correlation between MT and ER receptor was also detected (p=0.07), These data suggest that MT expression seems to be under hormonal control in normal endometrium; that it may modify p53 expression; and that it could be used as an additional biological marker indicating aggressive behaviour in endometrial lesions. Copyright (C) 2000 John Wiley & Sons, Ltd.
引用
收藏
页码:269 / 273
页数:5
相关论文
共 32 条
[1]  
AbdelMageed AB, 1996, CANCER GENE THER, V3, pO93
[2]  
ABELER VM, 1992, CANCER, V69, P488, DOI 10.1002/1097-0142(19920115)69:2<488::AID-CNCR2820690236>3.0.CO
[3]  
2-O
[4]   IMMUNOHISTOCHEMICAL DEMONSTRATION OF METALLOTHIONEIN IN NORMAL HUMAN BREAST-TISSUE AND BENIGN AND MALIGNANT BREAST-LESIONS [J].
BIER, B ;
DOUGLASJONES, A ;
TOTSCH, M ;
DOCKHORNDWORNICZAK, B ;
BOCKER, W ;
JASANI, B ;
SCHMID, KW .
BREAST CANCER RESEARCH AND TREATMENT, 1994, 30 (03) :213-221
[5]   IMMUNOHISTOCHEMICAL EVALUATION OF ESTROGEN AND PROGESTERONE-RECEPTOR CONTENT IN 183 PATIENTS WITH ENDOMETRIAL CARCINOMA .1. CLINICAL AND HISTOLOGIC CORRELATIONS [J].
CARCANGIU, ML ;
CHAMBERS, JT ;
VOYNICK, IM ;
PIRRO, M ;
SCHWARTZ, PE .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1990, 94 (03) :247-254
[6]  
CHERIAN MG, 1993, CANCER RES, V53, P922
[7]   PROGNOSTIC-SIGNIFICANCE OF HORMONE RECEPTORS IN ENDOMETRIAL CANCER [J].
CREASMAN, WT .
CANCER, 1993, 71 (04) :1467-1467
[8]   METALLOTHIONEIN EXPRESSION IN DUCT CARCINOMA IN-SITU OF THE BREAST [J].
DOUGLASJONES, AG ;
SCHMID, KW ;
BIER, B ;
HORGAN, K ;
LYONS, K ;
DALLIMORE, ND ;
MONEYPENNY, IJ ;
JASANI, B .
HUMAN PATHOLOGY, 1995, 26 (02) :217-222
[9]   LOCALIZATION OF METALLOTHIONEIN IN BREAST CARCINOMAS - AN IMMUNOHISTOCHEMICAL STUDY [J].
FRESNO, M ;
WU, WY ;
RODRIGUEZ, JM ;
NADJI, M .
VIRCHOWS ARCHIV A-PATHOLOGICAL ANATOMY AND HISTOPATHOLOGY, 1993, 423 (03) :215-219
[10]   IMMUNOHISTOCHEMICAL DETECTION OF METALLOTHIONEIN IN PRIMARY BREAST CARCINOMAS AND THEIR AXILLARY LYMPH-NODE METASTASES [J].
HAERSLEV, T ;
JACOBSEN, K ;
NEDERGAARD, L ;
ZEDELER, K .
PATHOLOGY RESEARCH AND PRACTICE, 1994, 190 (07) :675-681